viernes, 20 de noviembre de 2026
Out-of-Pocket Costs for Insulin Among People with Medicare Decreased by Half Between 2020 and 2024 Authors: Juliette Cubanski, Meredith Freed, and Anthony Damico Published: Nov 20, 2026
https://www.kff.org/medicare/out-of-pocket-costs-for-insulin-among-people-with-medicare-decreased-by-half-between-2020-and-2024/
This analysis examines out-of-pocket costs on insulin among Medicare Part D enrollees between 2020 and 2024 to assess changes over time as voluntary and mandatory insulin copay limits took effect. The implementation of these measures resulted in a substantial reduction in out-of-pocket spending by enrollees without low-income subsidies who used insulin, with out-of-pocket spending on insulin decreasing from $971 million to $506 million in the aggregate between 2020 and 2024 and from $54 to $25…
Two KFF Analyses Examine the Impact of Out-of-Pocket Spending Caps on Insulin in Medicare and Efforts to Extend Such Caps to Private Insurance
A new KFF analysis finds that federal measures enacted since 2021 to cap out-of-pocket insulin costs for people with Medicare Part D have substantially reduced what enrollees pay. The findings come as Congress considers legislation to extend similar protections to people with private insurance.
The analysis finds that out-of-pocket spending among insulin users in Part D who did not receive extra subsidies for low-income beneficiaries declined 54% between 2020 and 2024, from $54 to $25 per insulin prescription. Total out-of-pocket spending on insulin by these enrollees fell from nearly $1.0 billion in 2020 to $0.5 billion in 2024.
The reduction follows the implementation of a provision in the Inflation Reduction Act of 2022, signed by President Biden, that capped Medicare beneficiaries’ monthly out-of-pocket costs for insulin at $35 beginning in 2023, along with a separate voluntary program established under the first Trump administration that was in effect for some Medicare Part D enrollees from 2021 to 2023.
A second brief examines the evolution of efforts to cap out-of-pocket costs for insulin in the private insurance market, including existing state laws, federal legislation proposing a $35 monthly cap, and key considerations for policymakers assessing whether this approach may improve insulin affordability for people with private coverage.
Twenty-nine states and Washington, D.C. have enacted laws that cap cost-sharing for insulin for privately insured patients, beginning with Colorado in 2019. Additionally, some of these states have eliminated cost-sharing for insulin in certain types of ACA Marketplace plans and/or have implemented separate programs to help uninsured and underinsured patients afford their insulin. However, state regulations generally cannot reach the majority of people with employer coverage because they are in self-insured plans that fall under federal oversight.
Nationally, nearly 29 million adults in the U.S. have been diagnosed with diabetes, with 32% of them taking insulin to manage it.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario